Astragaloside effect on TGF-β1, SMAD2/3, and α-SMA expression in the kidney tissues of diabetic KKAy mice

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 6, 2015, Pages 6828-6834

  Wang, Yaning ^a,b   Lin, Chao ^b   Ren, Qiang ^b   Liu, Yunqi ^b   Yang, Xiangdong ^a  

^a SHANDONG UNIVERSITY   (China)

^b BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Astragaloside; Diabetic mellitus; TGF 1; SMA

Indexed keywords

ACTIN; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; HERBACEOUS AGENT; SMAD2 PROTEIN; SMAD2 PROTEIN, MOUSE; SMAD3 PROTEIN; SMAD3 PROTEIN, MOUSE; TGFB1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; ASTRAGALUS MEMBRANACEUS; C57BL MOUSE; CHEMISTRY; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; ISOLATION AND PURIFICATION; KIDNEY; MALE; MEDICINAL PLANT; METABOLISM; PATHOLOGY; PHYTOTHERAPY; SIGNAL TRANSDUCTION; TIME FACTOR;

ACTINS; ANIMALS; ASTRAGALUS MEMBRANACEUS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; FIBROSIS; KIDNEY; MALE; MICE, INBRED C57BL; PHYTOTHERAPY; PLANTS, MEDICINAL; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84938567400     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Wang JY, Gao YB, Zhang N, Zou DW, Wang P, Zhu ZY, Li JY, Zhou SN, Wang SC, Wang YY, Yang JK. miR-21 overexpression enhances TGF-beta1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Mol Cell Endocrinol 2014; 392: 163-172.
2. Araoka T, Abe H, Tominaga T, Mima A, Matsubara T, Murakami T, Kishi S, Nagai K, Doi T. Transcription factor 7-like 2 (TCF7L2) regulates activin receptor-like kinase 1 (ALK1)/Smad1 pathway for development of diabetic nephropathy. Mol Cells 2010; 30: 209-218.
3. Ding Z, Chen Z, Chen X, Cai M, Guo H, Chen X, Gong N. Adenovirus-mediated anti-sense ERK2 gene therapy inhibits tubular epithelial-mesenchymal transition and ameliorates renal allograft fibrosis. Transpl Immunol 2011; 25: 34-41.
4. He F, Yu L, Tong JR, Luo ZM, Zhu QZ, Wang Y, Zhang JL. Role of integrin-linked kinase in renal tubular epithelial-mesenchymal transition and the regulatory effect of urokinase on its expression in mice with obstructive nephropathy. Nan Fang Yi Ke Da Xue Xue Bao 2009; 29: 909-913.
5. Yin Y, Qi F, Song Z, Zhang B, Teng J. Ferulic acid combined with astragaloside IV protects against vascular endothelial dysfunction in diabetic rats. Biosci Trends 2014; 8: 217-226.
6. Chen J, Chen Y, Luo Y, Gui D, Huang J, He D. Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats. Eur J Pharmacol 2014; 736: 86-94.
7. Yamada Y, Muraki A, Oie M, Kanegawa N, Oda A, Sawashi Y, Kaneko K, Yoshikawa M, Goto T, Takahashi N, Kawada T, Ohinata K. Soymorphin-5, a soy-derived mu-opioid peptide, decreases glucose and triglyceride levels through activating adiponectin and PPARalpha systems in diabetic KKAy mice. Am J Physiol Endocrinol Metab 2012; 302: E433-440.
8. Li M, Yu L, She T, Gan Y, Liu F, Hu Z, Chen Y, Li S, Xia H. Astragaloside IV attenuates Toll-like receptor 4 expression via NF-kappaB pathway under high glucose condition in mesenchymal stem cells. Eur J Pharmacol 2012; 696: 203-209.
9. Qi W, Chen X, Poronnik P, Pollock CA. The renal cortical fibroblast in renal tubulointerstitial fibrosis. Int J Biochem Cell Biol 2006; 38: 1-5.
10. Weil EJ, Lemley KV, Mason CC, Yee B, Jones LI, Blouch K, Lovato T, Richardson M, Myers BD, Nelson RG. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int 2012; 82: 1010-1017.
11. Toyoda M, Najafian B, Kim Y, Caramori ML, Mauer M. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 2007; 56: 2155-2160.
12. Reidy K, Susztak K. Epithelial-mesenchymal transition and podocyte loss in diabetic kidney disease. Am J Kidney Dis 2009; 54: 590-593.
13. Fukuda A, Chowdhury MA, Venkatareddy MP, Wang SQ, Nishizono R, Suzuki T, Wickman LT, Wiggins JE, Muchayi T, Fingar D, Shedden KA, Inoki K, Wiggins RC. Growth-dependent podocyte failure causes glomerulosclerosis. J Am Soc Nephrol 2012; 23: 1351-1363.
14. Zou MS, Yu J, Nie GM, He WS, Luo LM, Xu HT. 1, 25-dihydroxyvitamin D3 decreases adriamycin-induced podocyte apoptosis and loss. Int J Med Sci 2010; 7: 290-299.
15. Lv L, Wu SY, Wang GF, Zhang JJ, Pang JX, Liu ZQ, Xu W, Wu SG, Rao JJ. Effect of astragaloside IV on hepatic glucose-regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin. Phytother Res 2010; 24: 219-224.
16. Yuan W, Zhang Y, Ge Y, Yan M, Kuang R, Zheng X. Astragaloside IV inhibits proliferation and promotes apoptosis in rat vascular smooth muscle cells under high glucose concentration in vitro. Planta Med 2008; 74: 1259-1264.
17. Salmon AH, Neal CR, Harper SJ. New aspects of glomerular filtration barrier structure and function: five layers (at least) not three. Curr Opin Nephrol Hypertens 2009; 18: 197-205.
18. Xavier S, Niranjan T, Krick S, Zhang T, Ju W, Shaw AS, Schiffer M, Bottinger EP. TbetaRI independently activates Smad- and CD2AP-dependent pathways in podocytes. J Am Soc Nephrol 2009; 20: 2127-2137.
19. Piwkowska A, Rogacka D, Audzeyenka I, Jankowski M, Angielski S. High glucose concentration affects the oxidant-antioxidant balance in cultured mouse podocytes. J Cell Biochem 2011; 112: 1661-1672.
20. Tan S, Wang G, Guo Y, Gui D, Wang N. Preventive Effects of a Natural Anti-Inflammatory Agent, Astragaloside IV, on Ischemic Acute Kidney Injury in Rats. Evid Based Complement Alternat Med 2013; 2013: 284025.
21. Zheng R, Deng Y, Chen Y, Fan J, Zhang M, Zhong Y, Zhu R, Wang L. Astragaloside IV attenuates complement membranous attack complex induced podocyte injury through the MAPK pathway. Phytother Res 2012; 26: 892-898.
22. Qi W, Niu J, Qin Q, Qiao Z, Gu Y. Astragaloside IV attenuates glycated albumin-induced epithelial-to-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cells. Cell Stress Chaperones 2014; 19: 105-114.
23. Meng LQ, Tang JW, Wang Y, Zhao JR, Shang MY, Zhang M, Liu SY, Qu L, Cai SQ, Li XM. Astragaloside IV synergizes with ferulic acid to inhibit renal tubulointerstitial fibrosis in rats with obstructive nephropathy. Br J Pharmacol 2011; 162: 1805-1818.
24. Gui D, Huang J, Guo Y, Chen J, Chen Y, Xiao W, Liu X, Wang N. Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-kappaB-mediated inflammatory genes expression. Cytokine 2013; 61: 970-977.